Income statement
USD
Annual
| Metric | 2018 | 2017 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 81K | 819K | 67M | 7M | 0 |
| Gross Profit | 24K | 386K | 63M | 6M | 0 |
| Operating Income | -196K | -3M | 26M | 3M | -3M |
| EBITDA | -139K | -3M | 19M | 3M | -401K |
| Net Income | -566K | -3M | -12M | 230K | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Praxsyn Corporation (PXYN) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -90.1%, EPS growth of +83.3%, a dividend yield of 0.0%. What stands out right now is revenue -90.1%, EPS +83.3%, free cash flow 0.0% with operating margin -240.9% and ROIC -4.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PXYN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PXYN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PXYN Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PXYN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$1.2M
-629.9% YoY
Free Cash Flow
-$2.2M
-7.5% YoY
Revenue Growth
-90.1%
EPS Growth
+83.3%
Gross Margin
29.4%
Net Margin
-695.5%
Income statement
USD
| Metric | 2018 | 2017 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 81K | 819K | 67M | 7M | 0 |
| Gross Profit | 24K | 386K | 63M | 6M | 0 |
| Operating Income | -196K | -3M | 26M | 3M | -3M |
| EBITDA | -139K | -3M | 19M | 3M | -401K |
| Net Income | -566K | -3M | -12M | 230K | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2018 | 2017 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4K | 15K | 1M | 37K | 82K |
| Total Assets | 11M | 11M | 17M | 5M | 136K |
| Total Liabilities | 9M | 8M | 15M | 10M | 3M |
| Shareholder Equity | 3M | 3M | 2M | -5M | -3M |
| Total Debt | 2M | 2M | 4M | 6M | 655K |
| Net Debt | 2M | 2M | 3M | 6M | 574K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-7.3% YoY
Capital Expenditures
98K
-11.8% YoY
Free Cash Flow
2M
-7.5% YoY
Key ratios
Gross Margin
29.4%
Operating Margin
-240.9%
Net Margin
-695.5%
ROE
-20.2%
Debt / Equity
0.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.